Highlights of the 36th EANM Annual Congress 2023, from hometown Vienna, Austria: “A SYMPHONY OF SCIENCE”
David Kersting, Silvia Morbelli, Sophie E. M. Veldhuijzen van Zanten & Hein J. Verberne
Advancements in Diagnostics
Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
7th Theranostics World Congress – Santiago, Chile
March […]
Focus on FAPI Newsletter – Q4 2024
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Dear FAPI Community,
We are looking forward to a […]
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous Tumor
Rainer Hamacher, Kim M Pabst, Phyllis F Cheung, Christoph E Heilig, Jennifer Hüllein, Sven-Thorsten Liffers, […]
18F-FAPI-04 Outperforms 18F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma
Xiang Li, Na Lu, Lili Lin, Yiwen Chen, Shuye Yang, Huatao Wang, Xinyuan Liu, Chengyi […]
Focus on FAPI Newsletter – Q2 2023
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study Gallery68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study
68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study
Ling Chen, Shan Zheng, Linying Chen, Sunwang Xu, Kunlin Wu, Lingjun Kong, Jiajie Xue, Xiangjin […]
Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol GalleryGallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol
Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol
Aashna Karbhari, Sherly Mosessian, Kamaxi H. Trivedi, Frank Valla Jr, Mark Jacobson, Mark J. Truty, […]
68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study Gallery68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study
68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study
Ling Chen, Shan Zheng, Linying Chen, Sunwang Xu, Kunlin Wu, Lingjun Kong, Jiajie Xue, Xiangjin […]
68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial Gallery68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial
68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial
Lukas Kessler, Nader Hirmas, Kim M. Pabst, Rainer Hamacher, Justin Ferdinandus, Benedikt M. Schaarschmidt, Aleksandar […]